Under a recently signed agreement, genetic sequences for antibodies discovered in the Vanderbilt Vaccine Center will be provided to AstraZeneca for identification of the most promising candidates for clinical assessment and future clinical use.
Under a recently signed agreement, genetic sequences for antibodies discovered in the Vanderbilt Vaccine Center will be provided to AstraZeneca for identification of the most promising candidates for clinical assessment and future clinical use.